Chong Kun Dang Pharmaceutical
Chong Kun Dang Pharmaceutical Corp. engages in the manufacturing, marketing, and sales of medicines in South Korea and internationally. The company provides prescription drugs for anti-hypertension, anti-hyperlipidemia, anti-diabetics, and immunosuppressants; over-the-counter medicine comprising headache remedies, dewormers, digestive aids, and vitamins; probiotics and Omega-3 supplements; and he… Read more
Chong Kun Dang Pharmaceutical (185750) - Total Liabilities
Latest total liabilities as of September 2025: ₩576.36 Billion KRW
Based on the latest financial reports, Chong Kun Dang Pharmaceutical (185750) has total liabilities worth ₩576.36 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Chong Kun Dang Pharmaceutical - Total Liabilities Trend (2016–2024)
This chart illustrates how Chong Kun Dang Pharmaceutical's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Chong Kun Dang Pharmaceutical Competitors by Total Liabilities
The table below lists competitors of Chong Kun Dang Pharmaceutical ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Accel Entertainment Inc
NYSE:ACEL
|
USA | $852.80 Million |
|
Shenzhen MYS Environmental Protection & Technology Co Ltd
SHE:002303
|
China | CN¥2.73 Billion |
|
Zhejiang Baoxiniao Garment Co Ltd
SHE:002154
|
China | CN¥2.26 Billion |
|
Bikaji Foods International Limited
NSE:BIKAJI
|
India | ₹5.99 Billion |
|
Jiayuan Science and Technology Co.Ltd.
SHE:301117
|
China | CN¥222.17 Million |
|
Hubei Kailong Chemical Group Co Ltd
SHE:002783
|
China | CN¥4.54 Billion |
|
Laan & Spar Bank AS
CO:LASP
|
Denmark | Dkr37.37 Billion |
|
Banco de Valores SA
BA:VALO
|
Argentina | AR$2.14 Trillion |
Liability Composition Analysis (2016–2024)
This chart breaks down Chong Kun Dang Pharmaceutical's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.89 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.61 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.38 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Chong Kun Dang Pharmaceutical's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Chong Kun Dang Pharmaceutical (2016–2024)
The table below shows the annual total liabilities of Chong Kun Dang Pharmaceutical from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩562.39 Billion | -4.16% |
| 2023-12-31 | ₩586.79 Billion | +16.52% |
| 2022-12-31 | ₩503.59 Billion | +4.72% |
| 2021-12-31 | ₩480.89 Billion | +21.82% |
| 2020-12-31 | ₩394.74 Billion | +20.94% |
| 2019-12-31 | ₩326.40 Billion | +16.32% |
| 2018-12-31 | ₩280.60 Billion | +2.44% |
| 2017-12-31 | ₩273.91 Billion | -4.71% |
| 2016-12-31 | ₩287.45 Billion | -- |